Studien Neuroendokrine Tumoren

COMPETE

Titel deutsch
Titel englisch A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).
Phase/Biobank/ect.
Studienleiter Dr. med. Attila Kollar
Study-Nurse Yaël Balderer
Back-up Antje Kramer
Status aktiv seit 27.12.2017
BASEC Nummer 2017-00466
KOFAM 39026
WHO-Register-Nummer EUCTR2016-001897-13-NL
Insel-Nummer 3421